Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer

Gynecologic Oncology

Volumn 108, Issue 2, 2008, Pages 317-325

  Thomas, Gillian ^a   Ali, Shamshad ^b   Hoebers, Frank J P ^c   Darcy, Kathleen M ^b   Rodgers, William H ^d   Patel, Malti ^e   Abulafia, Ovardia ^f   Lucci III, Joseph A ^g   Begg, Adrian C ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d UNIVERSITY OF MARYLAND   (United States)

^e JURAVINSKI CANCER CENTRE   (Canada)

^f SUNY DOWNSTATE MEDICAL CENTER   (United States)

^g UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma of cervix; Erythropoietin; Platinum DNA adducts; Thromboembolism

Indexed keywords

CISPLATIN; ERYTHROPOIETIN; PLATINUM; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BIOASSAY; BLOOD TRANSFUSION; CANCER CONTROL; CHEEK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE FREE SURVIVAL; DNA ADDUCT; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOEMBOLISM; UTERINE CERVIX CANCER;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; DNA ADDUCTS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; THROMBOEMBOLISM; UTERINE CERVICAL NEOPLASMS;

EID: 38649128164     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.10.011     Document Type: Article

References (43)

1. Thomas G.M. Improved treatment for cervical cancer-concurrent chemotherapy and radiotherapy. N Engl J Med 340 15 (1999) 1198-1200
2. Grogan M., Thomas G.M., Melamed I., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 8 (1999) 1528-1536
3. Pearcey R., et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20 4 (2002) 966-972
4. Hirst D.G., Hazlehurst J.L., and Brown J.M. The effect of alterations in hematocrit on tumor sensitivity to X-rays. Int J Radiat Oncol Biol Phys 46 (1984) 345-354
5. Hirst D.G. Anemia: a problem or an opportunity in radiotherapy. Int J Radiat Oncol Biol Phys 12 (1986) 2009-2017
6. Hewitt H.B., and Blake E. Effect of induced host anemia on the viability and radiosensitivity of murine malignant cells in vivo. Br J Cancer 25 (1971) 323-336
7. Hill R.P., Bush R.S., and Yeung P. The effect of anemia on the fraction of hypoxic cells in an experimental tumor. Br J Radiol 44 (1971) 299-304
8. Acker T., and Plate K.H. Hypoxia and hypoxia inducible factors (HIF) as important regulators of tumor physiology. Cancer Treat Res 117 (2004) 219-248
9. Grau C., and Overgaard J. Significance of hemoglobin concentrations for treatment outcome. In: Molls M., and Vaupel P. (Eds). Blood perfusion and microenvironment of human tumors. Implications for clinical radiooncology (1998), Springer, Berlin 101-112
10. Dunst J., Pigorsch S., Hansgen G., et al. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Does anemia stimulate angiogenesis?. Strahlenther Onkol 175 3 (1999) 93-96
11. Brizel D.M., Dodge R.K., Clough R.W., et al. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53 2 (1999) 113-117
12. Dunst J., Kuhnt T., Strauss H.G., et al. Anemia in cervical cancers: impact on survival, patterns of relapse, and association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys. 56 3 (2003) 778-787
13. Haensgen G., Krause U., Becker A., et al. Tumor hypoxia, p53, and prognosis in cervical cancers. Int J Radiat Oncol Biol Phys 50 4 (2001) 865-872
14. Bush R.S., Jenkin R.D., Allt W.E., et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 37 Suppl. III (1978) 302-306
15. Winter III W.E., Maxwell G.L., Tian C., et al. Association of hemoglobin level with survival in cervical carcinoma patients treated with concurrent cisplatin and radiotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol 94 2 (2004) 495-501
16. Reed E., Yuspa S.H., Zwelling L.A., Ozols R.F., and Poirier M.C. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J Clin Invest 77 (1986) 545-550
17. Reed E., Ozols R.F., Tarone R., Yuspa S.H., and Poirier M.C. Platinum-DNA adducts in leucocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. Proc Natl Acad Sci U S A 84 (1987) 5024-5028
18. Reed E., Parker R.J., Gill I., et al. Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies. Cancer Res 53 (1993) 3694-3699
19. Schellens J.H., Ma J., Planting A.S., et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br J Cancer 73 (1996) 1569-1575
20. Gupta-Burt S., Shamkhani H., Reed E., et al. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation. Cancer Epidemiol Biomarkers Prev 2 (1993) 229-234
21. Motzer R.J., Reed E., Perera F., et al. Platinum-DNA adducts assayed in leukocytes of patients with germ cell tumors measured by atomic absorbance spectrometry and enzyme-linked immunosorbent assay. Cancer 73 11 (1994) 2843-2852
22. Bonetti A., Apostoli P., Zaninelli M., et al. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy. Clin Cancer Res 2 11 (1996) 1829-1835
23. Fisch M.J., Howard K.L., Einhorn L.H., and Sledge G.W. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival. Clin Cancer Res 2 6 (1996) 1063-1106
24. Blommaert F.A., Michael C., Terheggen P.M., et al. Drug-induced DNA modifications in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: interindividual variation and correlation with disease response. Cancer Res 53 23 (1993) 5669-5675
25. van de Vaart P.J.M., Belderbos J., de Jong D., et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 89 2 (2000) 160-166
26. Schoenfeld D. Sample-sizes for the proportional hazards regression model. Biometrics 39 2 (1983) 499-503
27. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
28. Crowley J. A note on some recent likelihoods leading to the log rank test. Biometrika 61 3 (1974) 533-538
29. Bland J.M., and Altman D.G. The logrank test. BMJ 328 7447 (2004) 1073
30. Cox D.R. Regression model and life-tables. J R Stat Soc B 34 (1972) 187-220
31. Agresti A. A survey of exact inference for contingency tables. Stat Sci 7 (1992) 131-177
32. Mehta C.R., and Patel N.R. Exact logistic regression: theory and examples. Stat Med 14 19 (1995) 2143-2160
33. Nordsmark M., and Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol 43 4 (2004) 396-403
34. Jacobson G.M., Kamath R.S., Smith B.J., and Goodheart M.J. Thromboembolic events in patients treated with definitive chemotherapy and radiation therapy for invasive cervical cancer. Gynecol Oncol 6 2 (2005) 470-474
35. www.trends-in-medicine.com.
36. Anders J.C., Grigsby P.W., and Singh A. Cisplatin chemotherapy (without erythropoietin) and risk of life-threatening thromboembolic events in carcinoma of the uterine cervix: the tip of the iceberg? A review of the literature. Radiat Oncol 1 (2006) 14
37. Wun T., Law L., Harvey D., et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 98 7 (2003) 1514-1520
38. Henke M., Laszig R., Rube C., et al. To treat head and neck cancer patients with anemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet 362 9393 (2003) 1255-1260
39. Leyland-Jones B., Semiglazov V., Pawlicki M., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23 25 (2005) 5960-5972
40. Wright J.R., Ung Y.C., Julian J.A., et al. Randomized double-blind placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 9 (2007) 1027-1032
41. Khuri F.R. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 356 24 (2007) 2445-2448
42. Overgaard J. Interim analysis of DAHANCA 10. Danish head and neck cancer group. Available from (2006). http://conman.au.dk.dahanca/get_media_file.php?mediaid=125
43. Hans E.S., and Monk B.J. What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?. Gynecol Oncol 105 1 (2007) 3-6